Actively Recruiting
PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity
Led by Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Updated on 2024-01-10
100
Participants Needed
1
Research Sites
214 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of the current study is to evaluate the efficacy of combined regimen of GVHD prophylaxis with thymoglobulin in conditioning regimen and PTCY with ruxolitinib used after HSCT in patients with inborn errors of immunity (IEI)
CONDITIONS
Official Title
PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 60 months and less than 21 years
- Diagnosis of Nijmegen breakage syndrome (NBS) eligible for allogeneic HSCT
- Written informed consent signed by a parent or legal guardian
You will not qualify if you...
- Presence of a severe somatic disease that increases the risk of serious complications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
HSCT department
Moscow, Russia
Actively Recruiting
Research Team
D
Dmitry Balashov, MD, PhD
CONTACT
A
Alexandra Laberko, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here